U.S. Markets open in 4 hrs 14 mins
  • S&P Futures

    3,771.25
    -32.00 (-0.84%)
     
  • Dow Futures

    30,114.00
    -251.00 (-0.83%)
     
  • Nasdaq Futures

    11,538.50
    -102.25 (-0.88%)
     
  • Russell 2000 Futures

    1,760.70
    -20.80 (-1.17%)
     
  • Crude Oil

    86.01
    -0.51 (-0.59%)
     
  • Gold

    1,723.00
    -7.50 (-0.43%)
     
  • Silver

    20.74
    -0.36 (-1.70%)
     
  • EUR/USD

    0.9950
    -0.0036 (-0.3582%)
     
  • 10-Yr Bond

    3.6170
    0.0000 (0.00%)
     
  • Vix

    29.42
    -0.68 (-2.26%)
     
  • GBP/USD

    1.1417
    -0.0058 (-0.5012%)
     
  • USD/JPY

    144.3480
    +0.1490 (+0.1033%)
     
  • BTC-USD

    20,145.79
    +283.12 (+1.43%)
     
  • CMC Crypto 200

    456.31
    +10.88 (+2.44%)
     
  • FTSE 100

    7,005.34
    -81.12 (-1.14%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Atreca Inks Licensing Pact With Gates Research On Malaria Antibody

·1 min read
  • Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria.

  • MAM01/ATRC-501 is a monoclonal antibody entering preclinical development.

  • Under the agreement, Gates MRI will lead the development of MAM01/ATRC-501 and receive commercial rights in GAVI-eligible countries.

  • Atreca will retain commercial rights in the U.S., Europe, and parts of Asia.

  • MAM01/ATRC-501 is an engineered version of a human monoclonal antibody generated following vaccination with Mosquirix and identified via Atreca's discovery platform.

  • MAM01/ATRC-501 targets the malaria circumsporozoite protein (CSP) and has been shown to protect animals against malaria infection in multiple in vivo mouse studies.

  • Price Action: BCEL shares are up 4.96% at $5.50 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.